"Octreotide" 'ana. Na Ke Kumu no ka hoʻohana a me ka hōʻikeʻano

Medicine "Octreotide", ke kumukuai o ka i mea oi ma mua o 3000 p., E kokua i ka uhi i ka pathologically māhuahua? Iecaianoaaiiie o ka ulu hōmona, serotonin a me peptides gastroenteropankreaticheskoy kahua. Ke huahana i kaʻaoʻaoʻelua hopena.

hoike

E hoomakaukau ai "Octreotide" Ua häʻawi mai me ka acromegaly (ma ka hihia o ka ole o keʻoki kino, dopamine agonist Inc, pāhawewe Inc no inoperable a me nā mea maʻi hooleʻoki kino), carcinoid hikoko, a me nā loko gastroenteropankreaticheskoy'ōnaehana ke komo pū carcinoid maʻi pale. E hoʻokomo nāʻikepili o ka li nui i loko o ka naau kiwikā, excessive? Anoe? O kaiakū capillaries, ili pigmentation, maʻi enteritis, telangiectasia, li nui i loko o ka uuku liʻiliʻi. Prescribers me refractory diarrhea ma kōkua iā ia, nā mea maʻi. Paipaiʻano "Octreotide" (kuhi no ka hoʻohana ka mea, keʻae i) no ka Kāohiʻana o complications ma hope oʻoki kino ma luna o ka pancreas. Ma nāʻikepili nā hikoko, pu ma ka hypersecretion somatoliberin, vasoactive intestinalʻakika'amino, gastrinoma, glyukanomy.

dosing regimen

O ia hoʻi, "Octreotide" manual i ke heluhelu lawelawe subcutaneously. Laʻau heluna - 0.05-0.1 mg. I ka wā mawaena ma waena o injections - ewalu i he umikumamalua hora. Mahope paha ua hana nānā 'ana i nā hoailona malama mana hoʻomalu ma luna o ka maʻiʻo o ka ulu ana hōmona i loko o ke koko, a ma hope o ke kālailai i ka tolerability a me ka lapaʻau hoike ana. Ka mea e pono ai ke mahele lāʻau no ka lā no ka hapanui e hoomanawanui i - 0.2-0.3 mg. ʻO kā mākou dala no lā - 1.5 mg. I mea e pale aku complications o ka lāʻau ua lawelawe kekahi hola mua laparotomy. Ma hope o ka pahu kui 'uao i hana,ʻekolu manawa i ka lā i loko o ka mahele lāʻau o 0,1 mg. Duration o ka papa - i nā lāʻehiku. I ka wa elemakule, laʻau heluna hoʻoponopono mea pono.

"Octreotide" ka lapaʻauʻia. Na Ke Kumu no ka hoʻohana. Adverse reactions

Ka hope ke kāhea anorexia, cramps (kena ae la ia e ka pahikaua contraction o ala apuupuu Muscle ma na nā loko) i loko o ka abdomen, ka luaʻi, nausea, steatorrhea, diarrhea. I loko nō o ka mea ulu ma e auaaeaiea me na feces momona, ma ka hana, he mea ole PAaIEN i lōʻihi-makahiki hoʻohana ana i ka lāʻau 'hiki i malabsorption. Kekahi nā mea maʻi i symptoms like i ka huʻi intestinal iaʻi type. paipai lāʻau lawelawe ma waena oʻai ai i ka po, e emi i ka adverse reactions o gastrointestinal'āpana. Nā mea maʻi me ka hikoko o ka pituitary gland e e hoʻolako 'pili loa ua hoʻonānā aie i ka pahiki o ko lākou mau mea ulu me kaʻole pilikia makapō kuleana pili i. Ma ke kumu o ka Inc o hikoko i loko o nā loko gastroenteropankreaticheskoy'ōnaehana ma kekahi hihia kānāwai symptoms relapse. E kū'ē i ke kāʻei kua o ka hoomauia i o ka lāʻau "Octreotide" (kuhi no ka hoʻohana pihaʻi me keia mauʻikepili) hoʻoneʻe 'ia paha, e hana i nā pōhaku i loko o ka gallbladder. Ua mea no hoi e hiki IGT ka wā eʻai ana, i ka hooulu ana o ka hyperglycemia (paakiki type).